OncoMatch/Clinical Trials/NCT06395103
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Is NCT06395103 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies Zilovertamab vedotin for b-cell acute lymphoblastic leukemia.
Treatment: Zilovertamab vedotin — Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastoma and in pediatric and young adult participants with Ewing sarcoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Acute Lymphoblastic Leukemia
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Neuroblastoma
Sarcoma
Demographics
Prior therapy
Cannot have received: radiation therapy
Received prior radiotherapy within 4 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities.
Cannot have received: systemic anticancer therapy
Exception: except for prophylactic intrathecal chemotherapy and/or cytoreductive therapy with steroids/hydroxyurea
Received prior systemic anticancer therapy including investigational agents within 4 weeks before the first dose of study intervention (except for prophylactic intrathecal chemotherapy and/or cytoreductive therapy with steroids/hydroxyurea).
Cannot have received: investigational agent
Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Children's Hospital Los Angeles ( Site 1006) · Los Angeles, California
- Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 1016) · Aurora, Colorado
- Yale New Haven Hospital ( Site 1012) · New Haven, Connecticut
- Johns Hopkins All Children's Hospital ( Site 1025) · St. Petersburg, Florida
- University of Iowa-Holden Comprehensive Cancer Center ( Site 1017) · Iowa City, Iowa
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06395103 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy, systemic anticancer therapy, investigational agent disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 25 years or younger and at least 0 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify